Sign in

Private company

Jerini

Logo: Unknown author Unknown author, Public domain, via Wikimedia Commons3

German pharmaceutical company

Jerini AG was a pharmaceutical company based in Berlin, Germany, which focused on the discovery and development of novel peptide-based drugs. Using a proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursued disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini established a drug pipeline composed of its own programs as well as others in collaboration with partners.2 Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

1994Founded1
  • Industrypharmaceutical industry1
  • HeadquartersBerlin1
  • Founded inBerlin1
  • Websitewww.jerini.com
  • Legal formAktiengesellschaft1

See how the biggest companies compare on our leaderboards

Jerini 285 93
Photo: No machine-readable author provided. Toomai~commonswiki assumed (based on copyright claims)., CC BY-SA 3.0, via Wikimedia Commons5

Jerini AG was a pharmaceutical company based in Berlin, Germany, which focused on the discovery and development of novel peptide-based drugs. Using a proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursued disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini established a drug pipeline composed of its own programs as well as others in collaboration with partners. Jerini's commercialization strategy was to market new drugs in niche indications independently and in larger indications with partners. Jerini was acquired by Shire plc in 2008.2

Products and brands

  • icatibant

Listed on Wikidata.1

Based on its P2D platform, Jerini established several in-house development programs, to address indications within the ophthalmology, oncology, and inflammatory therapeutic areas. The most advanced of these programs targeted age-related macular degeneration (AMD), the leading cause of vision loss and blindness in people over the age of 55 in developed countries. Jerini's compound (JSM 6427) has shown significant efficacy in combating disease progression in preclinical models.

Jerini's proprietary Peptides-to-Drugs (P2D) technology was used to identify peptide drug lead structures and systematically transform them into peptidomimetic (injectable) and small-molecule (oral) drugs, depending on the indication. This enabled Jerini to develop novel drug candidates for diseases that were difficult to access using traditional drug discovery methods. The ability to produce both peptidomimetics and small molecule drugs as drug candidates has enabled the simultaneous development of drugs for acute and chronic treatments against the same target molecule (target).

From Wikipedia’s article on Jerini, shared under CC BY-SA 4.0.4

Timeline

  1. 1994Founded Founded in Berlin1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5